Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
Killing the Last 0.1%: Targeting Cancer Persister Cells
/in Preclinical Research/by MaxCancer therapy has a persistent blind spot. Tumors shrink, biomarkers improve, scans look clean—and yet relapse remains common. The reason is often a tiny population of surviving cells known as persisters. These cells are not genetically resistant. They are identical to the bulk tumor but enter a transient, drug-tolerant state that allows them to survive […]
Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer
/in Clinical Trial, Localized/by MaxThe phase III PrTK03 trial, reported in The Lancet Oncology, demonstrates that adding aglatimagene besadenovec (CAN-2409) plus valacyclovir to standard radiotherapy improves disease-free survival in patients with localized prostate cancer. Aglatimagene is an intratumoral adenoviral gene therapy that delivers the HSV-tk gene, enabling tumor cells to convert the prodrug valacyclovir into a cytotoxic metabolite that […]
Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by Max61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]
UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals
/in Clinical Trial, Metastatic, Phase 1/by MaxProstate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]
BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap
/in Observational, Retrospective studies/by MaxRecent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]
Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer
/in Preclinical Research/by MaxAcoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]
Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxRucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]
Real-World OPTYX Study: Sustained Castration and Rapid Testosterone Recovery with Relugolix
/in Observational/by MaxRelugolix (Orgovyx), the first oral androgen deprivation therapy approved for advanced prostate cancer, continues to show consistent performance in real-world settings. New data from the OPTYX study, a prospective observational analysis, provide further evidence on testosterone suppression, recovery, and PSA control in routine clinical practice. The study included 999 patients, predominantly with nonmetastatic disease and […]